Friday | 5 December, 2008
Stories about: PSIVIDA
- +
Past five years show life sciences industry growth 01/03/2006 13:05:46
The Australian life sciences industry has grown significantly in the past five years and shows signs of a positive future, according to the 15th edition of PricewaterhouseCoopers' quarterly BioForum report. - +
Novartis, Bausch & Lomb to promote pSivida blindness treatment 10/02/2006 15:25:03
Perth-based bio-nanotech company pSivida's (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) Retisert will be co-promoted in the US by Novartis Ophthalmics. - +
Psivida launches food technology spinout 01/12/2005 15:11:02
Perth-based bio-nanotech company Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has created a new spinout company, PsiNutria, to develop its silicon technology in the food industry. - +
Australian biotech hears the tiger's roar 21/11/2005 10:47:51
David Binning finds a wealth of opportunities for Australian integration with other Asian biotech industries. - +
The ASX: A haven for foreign biotech companies? 21/11/2005 10:43:00
The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports. - +
pSivida commences phase IIb clinical trials 31/10/2005 14:06:06
Perth-based bio-nanotech company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has commenced its phase IIb clinical trials with its BrachySil technology as a potential treatment for inoperable primary liver cancer. - +
pSivida signs licensing deal in China 28/10/2005 14:25:48
Perth-based bio-nanotech company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has signed a licence deal worth more than AUD$2.64 million with a US-based firm. - +
pSivida secures US$15m, US Medicare rebate approved 07/10/2005 14:58:15
pSivida has secured US$15 million (AUD$20 million) in additional funding from a New York institutional investor to assist in the development of its platform technology BioSilicon. - +
pSivida acquires US drug delivery company 04/10/2005 15:57:36
Perth nano-biotech company pSivida (ASX:PSD; NASDAQ:PSDV; Xetra:PSI) has agreed to purchase privately owned US drug delivery company Control Delivery Systems (CDS) for US$104 million (AUD$139 million), as part of its on-going US growth strategy. - +
Psivida to collaborate with US firm Cirrus 06/09/2005 13:15:00
Perth nano-biotech company Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has contracted North Carolina-based R&D organisation Cirrus Pharmaceuticals to develop a number of specific drug candidates formulated in Psivida's modified silicon product BioSilicon. - +
In brief: Meditech, Psivida, Regenera, Mesoblast 24/08/2005 14:59:34
Cancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing.
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
IDC Says Asia/Pacific Excluding Japan IT Market Will Remain The Bright Spot... 2008-12-04 15:04:00+11
AOC Launches 18.5” Widescreen Green 16:9 LCD Monitor in Australia and New Zealand 2008-12-03 15:30:00+11
“Just Graphics” isn’t enough any more 2008-11-28 15:02:00+11
Capture and Digitize Your Treasure Moments ~ Compro VideoMate C200 USB A/V Capture Stick 2008-11-26 12:37:00+11
AOC's Widescreen 22" LCD Monitor with All-Aluminum Chassis: Zifas 2218Ph - Flexible flair for discerning users 2008-11-24 13:30:00+11
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector.
